Novartis Investigative Site

Nixa, Missouri 65714-7807

0 studies enrolling now · 2 studies all time

What they study most

Relapsing Forms of Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis

Studies at this site

• Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis. — Completed
• A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis — Completed